metformin has been researched along with Seizures in 7 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Seizures: Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin was injected intraperitoneally in dose of 200mg/kg along with alternate-day PTZ." | 5.40 | Metformin protects against seizures, learning and memory impairments and oxidative damage induced by pentylenetetrazole-induced kindling in mice. ( Liu, LM; Wang, WP; Xu, F; Xu, XC; Zhang, WL; Zhao, RR, 2014) |
| "We searched PubMed, SCOPUS, Sciences Direct, and grey literature in order to explore articles published in English from January 2010 to November 2018, using key terms "epilepsy," "seizure," "metformin," "oral hypoglycemic agents," and "oral antidiabetic drugs"." | 5.01 | The Effect of Metformin in Experimentally Induced Animal Models of Epileptic Seizure. ( Gebre, AK; Surur, A; Wondafrash, DZ; Yimer, EM, 2019) |
| "CA6 and CA12 (p." | 1.91 | Anticonvulsant Profile of Selected Medium-Chain Fatty Acids (MCFAs) Co-Administered with Metformin in Mice in Acute and Chronic Treatment. ( Nieoczym, D; Pieróg, M; Samorek-Pieróg, M; Socała, K; Wlaź, P; Wyska, E, 2023) |
| "In PTZ-induced acute seizures model, behavioral assay showed that chronic metformin treatment decreased the mortality, and LFPs recording showed that chronic metformin treatment shortened the duration of generalized tonic-clonic seizures and prolonged the duration of postictal depression." | 1.46 | Chronic metformin treatment facilitates seizure termination. ( Hu, Y; Li, Y; Wang, X; Yang, Y; Zhang, Y; Zheng, F; Zhu, B, 2017) |
| "Metformin was injected intraperitoneally in dose of 200mg/kg along with alternate-day PTZ." | 1.40 | Metformin protects against seizures, learning and memory impairments and oxidative damage induced by pentylenetetrazole-induced kindling in mice. ( Liu, LM; Wang, WP; Xu, F; Xu, XC; Zhang, WL; Zhao, RR, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Jurca, CM | 1 |
| Kozma, K | 1 |
| Petchesi, CD | 1 |
| Zaha, DC | 1 |
| Magyar, I | 1 |
| Munteanu, M | 1 |
| Faur, L | 1 |
| Jurca, A | 1 |
| Bembea, D | 1 |
| Severin, E | 1 |
| Jurca, AD | 1 |
| Pieróg, M | 1 |
| Socała, K | 1 |
| Nieoczym, D | 1 |
| Wyska, E | 1 |
| Samorek-Pieróg, M | 1 |
| Wlaź, P | 1 |
| Nesci, V | 1 |
| Russo, E | 1 |
| Arcidiacono, B | 1 |
| Citraro, R | 1 |
| Tallarico, M | 1 |
| Constanti, A | 1 |
| Brunetti, A | 1 |
| De Sarro, G | 1 |
| Leo, A | 1 |
| Mehrabi, S | 1 |
| Sanadgol, N | 1 |
| Barati, M | 1 |
| Shahbazi, A | 1 |
| Vahabzadeh, G | 1 |
| Barzroudi, M | 1 |
| Seifi, M | 1 |
| Gholipourmalekabadi, M | 1 |
| Golab, F | 1 |
| Yimer, EM | 1 |
| Surur, A | 1 |
| Wondafrash, DZ | 1 |
| Gebre, AK | 1 |
| Zhao, RR | 1 |
| Xu, XC | 1 |
| Xu, F | 1 |
| Zhang, WL | 2 |
| Liu, LM | 1 |
| Wang, WP | 1 |
| Yang, Y | 1 |
| Zhu, B | 1 |
| Zheng, F | 1 |
| Li, Y | 1 |
| Zhang, Y | 1 |
| Hu, Y | 1 |
| Wang, X | 1 |
2 reviews available for metformin and Seizures
| Article | Year |
|---|---|
Tuberous Sclerosis, Type II Diabetes Mellitus and the PI3K/AKT/mTOR Signaling Pathways-Case Report and Literature Review.
Topics: Adolescent; Adult; Diabetes Mellitus, Type 2; Epilepsy; Female; Humans; Infant; Metformin; Phosphati | 2023 |
The Effect of Metformin in Experimentally Induced Animal Models of Epileptic Seizure.
Topics: Animals; Anticonvulsants; Behavior; Epilepsy; Humans; Metformin; Models, Animal; Seizures | 2019 |
5 other studies available for metformin and Seizures
| Article | Year |
|---|---|
Anticonvulsant Profile of Selected Medium-Chain Fatty Acids (MCFAs) Co-Administered with Metformin in Mice in Acute and Chronic Treatment.
Topics: AMP-Activated Protein Kinases; Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relat | 2023 |
Metabolic Alterations Predispose to Seizure Development in High-Fat Diet-Treated Mice: the Role of Metformin.
Topics: Animals; Anxiety; Avoidance Learning; Behavior, Animal; Blood Glucose; Body Composition; Depression; | 2020 |
Evaluation of metformin effects in the chronic phase of spontaneous seizures in pilocarpine model of temporal lobe epilepsy.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Epilepsy, Temporal Lobe; Male; Metformin; Pilocarp | 2018 |
Metformin protects against seizures, learning and memory impairments and oxidative damage induced by pentylenetetrazole-induced kindling in mice.
Topics: Animals; Antioxidants; Brain; Convulsants; Glutathione; Kindling, Neurologic; Learning Disabilities; | 2014 |
Chronic metformin treatment facilitates seizure termination.
Topics: AMP-Activated Protein Kinases; Animals; Male; Metformin; Mice; Mice, Inbred BALB C; Pentylenetetrazo | 2017 |